ORLANDO, Viviana
 Distribuzione geografica
Continente #
NA - Nord America 322
EU - Europa 126
AS - Asia 14
AF - Africa 4
Totale 466
Nazione #
US - Stati Uniti d'America 316
IT - Italia 71
FR - Francia 21
DE - Germania 10
NL - Olanda 6
CA - Canada 5
IR - Iran 5
CN - Cina 4
FI - Finlandia 4
GB - Regno Unito 3
ZA - Sudafrica 3
ES - Italia 2
IE - Irlanda 2
MY - Malesia 2
PK - Pakistan 2
SE - Svezia 2
UA - Ucraina 2
AT - Austria 1
BE - Belgio 1
LT - Lituania 1
MX - Messico 1
UG - Uganda 1
VN - Vietnam 1
Totale 466
Città #
Fairfield 41
Rome 36
Buffalo 29
Houston 27
Santa Cruz 22
Ashburn 21
Woodbridge 21
Seattle 20
Ann Arbor 10
Cambridge 10
Wilmington 7
Las Vegas 6
Chicago 5
Amsterdam 4
Clearwater 4
Helsinki 4
Phoenix 4
San Francisco 4
Bari 3
Beijing 3
Council Bluffs 3
Des Moines 3
Muizenberg 3
New York 3
Ottawa 3
Paris 3
Boardman 2
Cattolica 2
Cinisello Balsamo 2
Cosenza 2
Dallas 2
Dublin 2
Keningau 2
Los Angeles 2
Mountain View 2
Padula 2
Portland 2
Riva 2
San Diego 2
Stockholm 2
Toronto 2
University Park 2
Venezia 2
Annapolis 1
Aprilia 1
Atherstone 1
Austin 1
Bellevue 1
Bloomfield 1
Boulder 1
Cassano delle Murge 1
Centro 1
Charlotte 1
Cleveland 1
Dearborn 1
Dobldorf 1
Dulles 1
Falls Church 1
Fleming Island 1
Frankfurt am Main 1
Gloucester 1
Herndon 1
Ho Chi Minh City 1
Indiana 1
Jacksonville 1
Jesolo 1
Lake Forest 1
Lequile 1
Lincolnshire 1
Liscate 1
Messina 1
Napoli 1
Nashville 1
New Providence 1
Oudenaarde 1
Padova 1
Palermo 1
Pontelandolfo 1
Providence 1
Puteaux 1
Scranton 1
Selargius 1
Shanghai 1
Vicenza 1
Yellow Springs 1
Totale 375
Nome #
Drug design and synthesis of first in class PDZ1 targeting NHERF1 inhibitors as anticancer agents, file e3835321-b62e-15e8-e053-a505fe0a3de9 163
Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: Implication in peripheral inflammation, file e3835319-f072-15e8-e053-a505fe0a3de9 114
Dysregulated homeostasis of acetylcholine levels in immune cells of RR-multiple sclerosis patients, file e3835317-5d20-15e8-e053-a505fe0a3de9 96
Anticancer activity of (S)-5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-oxo-1-((pyridin-4-ylmethyl)amino)propan-2-yl)-1H-indole-2-carboxamide (RS4690), a new dishevelled 1 inhibitor, file e383532e-2da4-15e8-e053-a505fe0a3de9 49
Novel N-(Heterocyclylphenyl)benzensulfonamide Sharing an Unreported Binding Site with T-Cell Factor 4 at the β-Catenin Armadillo Repeats Domain as an Anticancer Agent, file e481c586-3297-49db-842a-3459cd8a4226 19
Top-down n-doped carbon quantum dots for multiple purposes: Heavy metal detection and intracellular fluorescence, file e383532f-122d-15e8-e053-a505fe0a3de9 18
4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1H-pyrrol-1-yl)benzenesulfonamide, a Novel Carbonic Anhydrase and Wnt/β-Catenin Signaling Pathway Dual-Targeting Inhibitor with Potent Activity against Multidrug Resistant Cancer Cells, file 627e2e0f-3a39-4d2c-8fef-60960843e574 12
Toward an objective evaluation of cell transfection performance, file e3835311-f7ef-15e8-e053-a505fe0a3de9 5
Direct HPLC enantioseparation of chiral aptazepine derivatives on coated and bonded polysaccharide-based chiral stationery phases., file e3835311-c01c-15e8-e053-a505fe0a3de9 4
Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia, file e383532c-7033-15e8-e053-a505fe0a3de9 3
Design, synthesis and biological evaluation of PDZ1 targeting NHERF1 inhibitors as anticancer agents, file e3835324-0461-15e8-e053-a505fe0a3de9 2
Modulating intracellular acidification by regulating the incubation time of proton caged compounds, file e3835317-7f19-15e8-e053-a505fe0a3de9 1
Structure-activity relationship studies and in vitro and in vivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies, file e3835323-f9c0-15e8-e053-a505fe0a3de9 1
Totale 487
Categoria #
all - tutte 1.081
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.081


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201936 0 0 0 0 0 0 0 0 0 6 14 16
2019/202098 11 7 4 3 9 10 12 8 15 6 6 7
2020/202155 3 7 1 7 1 7 0 7 4 5 10 3
2021/2022124 5 3 13 18 13 1 1 10 8 3 31 18
2022/202394 7 5 20 11 6 11 10 7 6 2 3 6
2023/202473 9 11 4 3 10 9 6 15 2 4 0 0
Totale 487